Frequent injections in the eye can cause infection, inflammation, and glaucoma. Akari is developing PAS-nomacopan with potential for 4 or fewer doses a year for …
Frequent IVI Burdens
Patients experience significant burdens (fear, discomfort, disruptions to their lives) with geographic atrophy (GA) treatments that are dosed monthly or every …
GA and Loss of Central Vision
Geographic atrophy (GA) is sight threatening. It causes loss of central vision, development of scotomas (blind spots), reduced reading speed and night vision …
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK and LONDON, September 5, 2023(GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
NEW YORK and LONDON, August 18, 2023 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
